Molecular genomics technology provider Agena Bioscience has launched the CFTR 100+ panel, a multiplex genotyping solution designed to provide expanded coverage of CFTR variants.
“With evolving CFTR variant recommendations, laboratories are reassessing panel content to ensure alignment with current standards,” said Agena Bioscience VP of scientific affairs Darryl Irwin. “The CFTR 100+ panel provides expanded, guideline-aligned variant coverage while leveraging the established workflow and throughput capabilities of the MassArray system.”
The CFTR gene encodes the cystic fibrosis transmembrane conductance regulator, a chloride channel involved in epithelial ion transport. The CFTR gene encodes the cystic fibrosis transmembrane conductance regulator, a chloride channel involved in epithelial ion transport. Pathogenic variants in CFTR are associated with cystic fibrosis and related phenotypes.
Simultaneous analysis of over 100 CFTR variants within a single multiplex assay format is possible with the panel. The CFTR 100+ panel includes all variants recommended for carrier screening, as well as additional variants of interest.
The expansion aims to support broader variant representation across diverse populations while adhering to guidance and maintaining high-throughput workflows.
